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Abstract 
The development of long-circulating formulations of liposomes (S-liposomes), sterically stabilized with lipid derivatives of poly(ethyl- 
ene glycol) (PEG), has increased the likelihood that these liposomes, coupled to targeting ligands such as antibodies, could be used as 
drug carriers to deliver therapeutic drugs to specific target cell populations in vivo. We have developed a new methodology for attaching 
monoclonal antibodies to the terminus of PEG on S-liposomes. A new end-group functionalized PEG-lipid derivative pyridylthiopropi- 
onoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) was synthesized for this purpose. Incorporation of PDP-PEG- 
DSPE into S-liposomes followed by mild thiolysis of the PDP groups resulted in formation of reactive thiol groups at the periphery of the 
lipid vesicles. Efficient attachment of maleimide-derivatized antibodies took place under mild conditions even when the content of the 
functionalized PEG-lipid in S-liposomes was below 1% of total lipid. The resulting S-immunoliposomes showed efficient drug remote 
loading, slow drug release rates and increased survival times in circulation compared to liposomes lacking PEG. When antibodies 
recognizing several different umor-associated antigens were coupled to the PEG terminus of S-liposomes, a significant increase in the in 
vitro binding of liposomes to the target cells was observed. The binding of S-immunoliposomes containing entrapped oxorubicin to their 
target cell population resulted in increased cytotoxicity compared to liposomes lacking the targeting antibody. 
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1. Introduction 
Site-specific delivery of drugs to diseased cells can lead 
to significant reductions in drug toxicity, and increased 
therapeutic effects. Therapeutic applications of liposomal 
drug delivery systems have been extensively explored in 
recent years [1-5], and several methods have been devel- 
oped for attachment of antibodies (Ab) at the liposome 
surface [6-9] in attempts to target he liposomes in vivo to 
specific sites of drug actions. Attachment of Ab at the 
surface of classical formulations of liposomes results in 
their rapid removal from circulation by the cells of the 
mononuclear phagocyte system (MPS, also termed 
reticuloendothelial system) [10,11]. New formulations of 
sterically stabilized liposomes (SL) have been developed 
recently which have extended blood circulation times as a 
result of reduced rates and extents of uptake by MPS cells 
[12-15]. SL contain, as the key component, methoxy 
poly(ethylene glycol) distearoylphosphatidyletbanolamine 
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(mPEG-DSPE) (4-8 mol% of the total lipid). This results 
in coverage of the lipid vesicle surfaces with grafted 
amphipathic polymer chains. It is believed that the high 
mobility of the mPEG chains, associated with their confor- 
mational flexibility, and also their water-binding ability, 
contribute to the steric stabilization which is responsible 
for their prolonged survival times in circulation [ 16,17]. 
We were interested in developing methods for attach- 
ment of Ab to the surface of SL which would meet a 
number of important criteria for 'ideal immunoliposomes'. 
These include: simplicity and ease of preparation, mainte- 
nance of prolonged circulation half-lives, retention of tar- 
get recognition for the Ab, high coupling efficiency of the 
Ab to the liposomes, the ability to achieve high Ab 
densities at the liposome surface, the ability to achieve 
efficient drug remote loading, appropriate drug release 
characteristics, and compatibility with use in humans. 
Attachment of Ab at the surface of SL, in the phospho- 
lipid headgroup region, can result in some decrease in 
coupling efficiency and some loss of Ab recognition, 
particularly in the presence of high molecular weights of 
mPEG which can sterically hinder access of the Ab to the 
liposome surface during coupling procedures and/or ac- 
cess of the Ab binding region to its epitope after its 
attachment to the liposomes [8,18,19]. Because some of the 
antibody coupling methods in the literature fell consider- 
ably short of the ideal, when applied to SL, we have 
developed a new coupling method, specifically for use 
with SL, which forms S-immunoliposomes (SIL) by cova- 
lently coupling antibodies to the liposomes via a thioether 
bond at the PEG terminus (Fig. 1), rather than to the 
phospholipid headgroup region on the liposome surface. 
This new method comes close to meeting the criteria 
outlined above for ideal SIL. Attachment of proteins to the 
distal end of PEG terminus using a PEG-COOH construct 
has recently been described by two different groups, with 
retention of long-circulating half-lives and target binding 
[20,21]. 
2. Materials and methods 
2.1. Materials 
Distearoylphosphatidylethanolamine (DSPE) was pur- 
chased from Sygena, Cambridge, MA, disuccinimidylcar- 
bonate (DSC) from Fluka (Ronkonkoma, NY), and N- 
succinimidyl-3-(2-pyridyldithio)proprionate (SPDP) from 
Bioaffinity Systems (Rosco, IL). Heterobifunctional c~- 
amino-w-hydroxy-PEG was prepared by partial conversion 
of hydroxy end groups of PEG-2000 (Fluka) into primary 
amines [22], followed by ion-exchange purification accord- 
ing to Furukawa [23]. Amino-PEG-DSPE was prepared as 
described elsewhere [24]. 
Hydrogenated soy phosphatidylcholine (HSPC) and 
methoxy (polyethylene glycol) (2000) distearoylphos- 
PDP-PEG-LIPOSOME 
HS-PEG-LIPOSOME 
s 
Fig. 1. Schematic diagram of the coupling of a maleimide-activated 
antibody (MPB-Ab) with sterically stabilized liposomes containing PDP- 
PEG-DSPE. 
phatidylethanolamine (mPEG-DSPE) were obtained from 
Liposome Technology (Menlo Park, CA). mPEG-DSPE 
synthesis was described in [14]. Cholesterol (CHOL) and 
pyridyldithioproprionate dioleoylPE (PDP-DOPE) were 
purchased from Avanti Polar Lipids (Birmingham, AL). 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium br - 
mide (MTT), N-succinimidyl-4-(p-maleimidophenyl)- 
butyrate (SMPB) and sheep IgG, used as a source of 
antibody (Ab) were purchased from Sigma (St. Louis, 
MO). Doxorubicin was obtained from Adria Laboratories 
(Mississauga, Ontario). Na125I and cholesteryl [1,2(n)- 
3H]hexadecyl ether, 1.48-2.22 TBq/mmol (3H-CHE) was 
purchased from New England Nuclear (Mississauga, On- 
tario). Tyraminylinulin was synthesized and [125I]tyra- 
minylinulin (125I-TI) was prepared as previously described 
[25]. Iodobeads were purchased from Pierce (Rockford, 
IL). Monoclonal antibodies (mAb) 174H.64, B43.13 and 
M170 and the cell lines KLN 205 and Caov-3 were 
generous gifts of Biomira, Edmonton, AB. The cell line 
HCT-15 was purchased from American Type Culture Col- 
lection (Rockville, MD). All other chemicals were analyti- 
cal grade. 
2.2. Synthesis 
General methods 
TLC on silica gel G were visualized with iodine vapour, 
ninhydrin and Dragendorff [26] spray reagents, when ap- 
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propriate. NMR spectra was recorded on a 360 MHz 
Nicolet instrument. When it was important to detect he 
terminal OH group of PEG, DMSO-d 6 was used as a 
solvent [27], otherwise CDCI 3 was used. 
Preparation of PDP-PEG-OH 
SPDP (100 mg, 0.32 mmol) and a-amino-w-hydroxy- 
PEG (0.55 g, 0.275 mmol) dissolved in acetonitrile (2 ml) 
reacted at 25°C for 4 h. TLC of the reaction mixture 
(CHCI3/CH3OH, 8:2) showed disappearance of HzN- 
PEG-OH with appearance of a less polar, UV-absorbing 
new material (Rf = 0.80). The solvent was rotary evapo- 
rated and ethyl ether (50 ml) added. After overnight stor- 
age at 4 ° C white solid was collected and dried in vacuo 
over P205. Yield: 0.5 g (90%). 
H-NMR (DMSO-d6): 6~2.5 (CH2S, overlap w/  
DMSO), 3.01 (t, J=  7 Hz, CH2C = O, 2H), 3.20 (m, 
CH2NH, 2H), 3.51 (s, PEG, ~ 18OH), 4.52 (t, HO-PEG, 
IH), 7.24 (m, pyr, IH), 7.76 (m, pyr, 1H), 7.82 (m, pyr, 
IH), 7.99 (br m, NH, 1H), 8.45 (m, pyr, 1H) ppm. H-NMR 
(CDC13): 6 2.62 (t, J = 7 Hz, CHzSS,  2H), 3.08 (t, J = 7 
Hz, CH2C = O, 2H), 3.47 (m, CH2N, 2H), 3.64 (s, PEG, 
18OH), 6.78 (br s, NH, 1H), 7.10, (m, pyr, IH), 7.66 
(m, pyr, 2H), 8.49 (m, pyr, I H) ppm. 
Preparation of PDP-PEG-SC 
Meticulously dried PDP-PEG-OH (0.4 g, 0.18 mmol) 
was dissolved in acetonitrile (0.5 ml) and treated with DSC 
(81 rag, 0.31 mmol) and pyridine (62 ml, 0.79 mmol) 
overnight at 25 ° C. The product was precipitated with ethyl 
ether (40 ml) at 4 ° C, redissolved in ethyl acetate (4 ml) 
and precipitated with equal volume of ethyl ether at 4 ° C. 
The product was collected by filtration and dried in vacuo 
over P205. Yield: 330 mg, (85%). 
H-NMR (DMSO-d6): 6~2.5 (CH2SS, overlap w/  
DMSO), 2.81 (s, SC, 4H), 3.01 (t, J=  7 Hz, CH2C = O, 
2H), 3.20 (m, CH2NH, 2H), 3.51 (s, PEG, -- 18OH), 4.45 
(t, CH2-SC, 2H), 7.24 (m, pyr, 1H), 7.8 (m, pyr, 2H), 8.0 
(br m, NH, lH), 8.45 (m, pyr, 1H) ppm. H-NMR (CDC13): 
6 2.62 (t, J = 7 Hz, CH2SS, 2H), 2.83 (s, SC, 4H), 3.09 
(t,  J = 7 Hz, CH2C = O, 2H), 3.44 (m, CHzN, 2H), 3.64 
(s, PEG, ~ 18OH), 4.46 (m, CH2-SC, 2H), 6.73 (br s, 
NH, IH), 7.10, (m, pyr, 1H), 7.66 (m, pyr, 2H), 8.48 (m, 
pyr, 1H) ppm. 
Preparation of PDP-PEG-DSPE 
Method A. DSPE (36 mg, 0.043 mmol) was added to a 
solution of PDP-PEG-SC (100 rag, 0.042 mmol) in chloro- 
form (1 ml), followed by TEA (33 /zl, 0.237 mmol). The 
reaction mixture became clear during incubation at 40°C 
for l0 min. The solvent was evaporated and replaced with 
acetonitrile (5 ml). The cloudy solution was kept at 4°C 
overnight. To remove traces of insoluble DSPE the solu- 
tion was centrifuged and the clear solution separated. It
was then rotary evaporated under educed pressure, and the 
residue was dried in vacuo over  P205.  Yield: 130 mg 
(quantitative). 
Method B. To a solution of amino-PEG-DSPE hydrochlo- 
ride [24] (198 mg, 0.07 mmol) in acetonitrile (2 ml), SPDP 
(26 rag, 0.085 mmol) was added followed by TEA (30 ml. 
0.42 mmol). The solution was stirred overnight. The prod- 
uct (200 rag) in chloroform was loaded onto a silica (11 g) 
column. It was eluted with a step gradient of CH3OH in 
chloroform (5, 10, 15, and 20%, 100 ml each step). Yield: 
106 mg of pure product and 77 mg of a product contami- 
nated with a more polar material (R t. = 0.125). 
The purified products obtained by both methods were 
identical. 
TLC (CHC13/CH3OH/H20 90:18:2) R~.=0.52. H- 
NMR (CDCl3): 6 0.89 (t, J = 6.8 Hz, CH 3, 6H), 1.26 (s, 
CH 2, 56H), 1.58 (br m, CH2CH2C = O, 4H), 2.28 (2 
overlapping t, CH2C =O), 2.62 (t, J=  7 Hz, CH2SS, 
2H), 3.09 (t, J=  7 Hz, CH2C = O, 2H), 3.36 (br m, 
OCH2CHzN, 2H), 3.44 (m, CH2N, 2H), 3.64 (s, PEG, 
-- 18OH), 3.94 (br m, CH2CH2OP, 2H), 4.17 (dd, J ---- 7.0, 
12 HZ, glycerol CH2OP, 2H), 4.21 (m, CH2-O2CN, 2H), 
4.39 (dd, J = 3.2, 12 Hz, glycerol CH2OC = O, 2H), 5.20 
(m, CH, 1H), 6.73 (br, NH, 1H), 7.10, (m, pyr, 1H), 7.66 
(m, pyr, 2H), 8.48 (m, pyr, IH) ppm. 13C-NMR (CDCI3): 
6 14.0 (CH3), 22.7 (CHzCH3), 24.9 (CH2CH2C -- O), 
29.7 (CH2CH2CH2), 31.9 (CHzCH2CH3), 34.1 and 34.3 
(CHzC = O), 34.7 (SCH2CHzC = O), 35.6 (SCHzCH2C 
=O), 39.4 (CHzNHC=O), 42.4 (CHzNHCO2), 62.8 
(CH2OC = O), 63.4 (CHzOPO3) ,  64.2 (CH2OC = ON), 
69.9 (CHOC = O), 70.6 (PEG), 120.0 (C2 pyr), 137.0 (C3 
pyr), 120.8 (C4 pyr), 149.7 (C5 pyr), 156.6 (C = O of 
urethane), 159.8 (C1 pyr), 170.7 (C = O of amide), 173.0 
and 173.3 (C = O of esters) ppm. 
2.3. Preparation of immunoliposomes 
Liposome preparation 
Liposomes were prepared by hydrating dry lipid films 
in an appropriate buffer, at a lipid concentration f l0 mM. 
The resulting multivesicular p eparations were then passed 
through 0.08-0.1 tzm polycarbonate membranes (Nucle- 
pore, Pleasanton, CA or Poretics, Livermore, CA) using a 
Lipex extruder (Lipex Biomembranes, Vancouver, BC), to 
give primarily unilamellar vesicles of approx. 100 nm in 
diameter [28,29]. The resulting liposomes were sized by 
dynamic light scattering using a Brookhaven BI90 particle 
sizer (Brookhaven I struments, Holtsville, NY). 
lodination of antibody 
Ab (2 mg) was dissolved in 200 Izl of 25 mM Hepes, 
140 mM NaCl, pH 7.4 buffer. The Ab solution was mixed 
with 185 MBq of NaJZSI in a 2 ml reaction vial with 5 
Iodobeads for 1 h at room temperature (22 ° C). ~25I-Ab 
was purified by passage over a Sephadex G25 gel filtration 
column, eluting with the above buffer. 
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Preparation of maleimidophenylbutyrate-Ab (MPB-AB) 
Ab was dissolved in 25 mM Hepes, 140 mM NaCI, pH 
7.4 at concentration of 10 mg/ml  and trace amounts of 
1251-Ab were added. SMPB (25 mM in dimethylform- 
amide) was slowly added to the Ab solution at a molar 
ratio of 20:1 (SMPB/Ab) for 30 rain at room temperature. 
Unbound SMPB was removed and the pH lowered by 
passing the solution over a Sephadex G50 column in 25 
mM Hepes, 25 mM Mes, 140 mM NaCI, pH 6.7 buffer. 
Antibody conjugation 
Liposomes were composed of HSPC/CHOL/PDP-  
PEG-DSPE at a molar ratio of 2:1:0.02 with or without 4 
tool% mPEG-DSPE (total PEG lipid, 5 tool% of PL) or of 
HSPC/CHOL/PDP-DOPE, at a molar ratio of 2:1:0.02 
with or without 5 tool% mPEG-DSPE. In experiments to 
determine the coupling efficiency of the PDP-PEG-PE 
method, the ratio of PDP-PEG-DSPE and mPEG-DSPE 
were varied, keeping the total amount of PEG-lipids in the 
liposomes constant at 5 mole% of phospholipids (PL). 
Trace amounts of 3H-CHE was added to each liposome 
preparation and the PL concentration was calculated from 
the specific activity using a Beckman LS6800 Scintillation 
counter. 
Liposomes were hydrated with 100 mM sodium acetate, 
70 mM NaCI, pH 5.5 buffer. The pyridyldithio groups 
were reduced by the addition of dithiothreitol (DTT) to a 
final concentration of 20 mM for 30 rain at room tempera- 
ture. DTT was separated and the pH raised by passing the 
liposomes over a Sephadex G50 column eluted with 25 
mM Hepes, 25 mM Mes, 140 mM NaC1, pH 6.7 buffer. 
Thiolated liposomes (2 /zmol PL) were incubated 
overnight at room temperature with MPB-Ab (0.25-8 
nmol) at Ab/PL  molar ratios ranging from 1:250 to 
1:8000, at a final PL concentration of 2-4 mM. Unbound 
Ab was removed by passing the liposomes over a Sepharose 
CL-4B column with pH 7.4 buffer (25 mM Hepes, 140 
mM NaC1). The Ab to PL ratio was determined by count- 
ing for 125I-IgG and 3H-CHE. The amount of J25I in the 3H 
channel was subtracted from the total 3H counted and this 
overlap was kept below 10% of 3H. 
2.4. Properties of immunoliposomes 
Liposomes were composed of HSPC/CHOL/mPEG-  
DSPE/PDP-PEG-DSPE (2:1:0.08:0.02 molar ratio) or 
HSPC/CHOL/PDP-DOPE (2:1:0.02 molar ratio). Lipo- 
somes were hydrated with the aqueous pace label 125I-TI 
[30] and prepared as above, with diameters of 98-130 nm. 
Free ~25I-T1 was separated from the liposomes by chro- 
matography over a Ultragel AcA 34 column (IBF Biotech- 
nics, France) with 25 mM Hepes, 140 mM NaCI, pH 7.4 
buffer. MPB-Ab was then conjugated to PDP-containing 
liposomes at various ratios to give Ab surface densities of 
0-140 /xg Ab//xmol PL. 
In these experiments, the amount of Ab bound to the 
liposomes was determined by an adaptation of a fluo- 
rescamine assay, where an increase in fluorescence is 
observed when fluorescamine binds to a free amino group 
on a protein [31,32]. Briefly, 10 mg fluorescamine was 
dissolved in 50 ml of dry acetonitrile. One ml samples of 
SIL (0.2-1 mM PL) were mixed with 1 ml of fresh 
fluorescamine r agent for 15 min at room temp then I ml 
of ethanol was added. The relative fluorescence was deter- 
mined on a Perkin-Elmer MPF-4 spectrofluorimeter (EM 
475 rim, EX 395 rim). Protein concentrations were deter- 
mined from a standard curve using known concentrations 
of MPB-Ab (5-160 /xg/ml). 
Outbred female CD I(ICR)BR mice were purchased from 
Charles River Canada (St. Constant, Quebec) and main- 
tained in standard housing. Mice (three per group) were 
given a single bolus i.v. injection via the tail vein of 0.2 ml 
of SIL (0.5 /xmol PL/mouse) containing (1-3) .  105 cpm 
of 125I-TI. At different imes post-injection, animals were 
anaesthetized with halothane and sacrificed by cervical 
dislocation. Major organs (liver, spleen, lung, heart and 
kidney), blood (100 /xl), thyroid and carcass (remainder of 
the animal) were collected and counted for 125I label in a 
Beckman 8000 gamma counter. Blood correction factors 
[33], were applied to all samples. The data is expressed as 
the percentage of counts in each organ relative to the total 
counts remaining in vivo at each time point [30]. 
The blood elimination half life of SIL was calculated 
using the polyexponential curve stripping and least squares 
parameter estimation program RSTRIP (Micromath, Salt 
Lake City, USA). 
Doxorubicin loading and leakage studies 
For DXR loading experiments, liposomes were hy- 
drated in 155 mM ammonium sulfate at pH 5.5 [34]. The 
liposomes were then passed over a Sephadex G50 column 
equilibrated in 123 mM sodium citrate, pH 5.5. DXR (0.2 
rag/rag PL) was then added to the liposomes and the 
mixture was incubated at 65°C for 1 h. DXR-containing 
liposomes were separated from any remaining free DXR 
by passage over a Sephadex G50 column and eluted with 
123 mM sodium citrate pH 5.5 buffer. 
For leakage xperiments, DXR-loaded liposomes, com- 
posed of HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE 
(2:1:0.08:0.02 molar ratio), were labelled with trace 
amounts of 3H-CHE. Liposomes were coupled with ~25I- 
Sheep IgG (SIL[sheep IgG]) to give 88 /xg Ab//xmol PL, 
then mixed with 25% human plasma in 25 mM Hepes, 140 
mM NaCl, pH 7.4 at 0.6-1.2 mM PL and dialysed (Spec- 
tra/Por 2, 12000-14000 M r cut-off; Spectrum, Los An- 
geles, Ca) against 50 volumes of 25% human plasma. At 
various times, samples were removed and the external 
plasma volume exchanged. The amount of DXR remaining 
in the liposomes was determined by extracting the DXR in 
methanol and determining the absorbance at A492 rim. 
Uptake and cytotoxicit)' studies 
Murine squamous lung carcinoma (KLN 205), human 
ovarian adenocarcinoma (Caov-3), and human colon 
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adenocarcinoma (HCT-15) cell lines were grown as mono- 
layers in RPMI 1640 supplemented with I0% fetal bovine 
serum (Gibco BRL, Burlington, Ontario, Canada) at 37°C 
in a humidified atmosphere of 5% CO 2 in air. Cells were 
plated in triplicate onto 6-well plates (Falcon, Becton 
Dickinson, Lincoln Park, NJ) at (0.15-1). 106 cells/well 
on day 1. SIL were prepared by conjugating (see above), 
to the surface of SL (HSPC/CHOL/mPEG-DSPE/PDP-  
PEG-DSPE, 2:1:0.08:0,02 molar ratio), mAb specific to 
each cell line, i.e., mAb 174H.64, B43.13 or M170 for 
experiments involving KLN 205, Caov-3 or HCT-15, re- 
spectively. On the fourth day (or at the point where the 
cells just reach confluence), SIL[174H.64], SIL[B43.13] or 
SIL[MI70], labelled with 3H-CHE (0.1-0.4/zmol/ml),  in
PBS were added to each well of their targeted cell lines, 
respectively. In some instances, binding of SIL to cells 
was also measured in the presence of 10% FBS. After 1 h 
incubation at 37 ° C, cells were washed three times with 
phosphate-buffered saline, pH 7.4, trypsinized with 0.5 ml 
of 0.05% trypsin, placed in ACS scintillation fluid 
(Amersham, Oakville, Ontario), and counted in a Beckman 
LS-6800 counter. 
A colorimetric assay using a tetrazolium salt was used 
for the measurement of surviving and/or proliferating 
cells according to Mosmann [35]. Cells (KLN 205) were 
plated in 96-well plates (Coming, Coming, NY) on day 1. 
On the third day, cells were incubated with either free 
DXR, DXR entrapped in non-targeted liposomes (DXR-SL) 
or DXR entrapped in SIL[174H.64] (DXR-SIL[174H.64]) 
and the cells were incubated for 1 h or 24 h at 37°C in a 
humidified 5% CO 2 atmosphere. At the end of the incuba- 
tion, free or liposomal DXR was removed by gentle wash- 
ing with phosphate-buffered saline, pH 7.4, and the cells 
were further incubated for 47 h or 24 h respectively, for a 
total of 48 h. At the end of the incubation, a solution of 
MTT (0.5 mg MTT/ml  media) was added to each well. 
and the mixture was incubated at 37 ° C for 4 h. Acid-iso- 
propanol (100 /zl of 0.04 M HC1 in isopropanol) was 
added to each well and mixed thoroughly until all crystals 
were dissolved. The plates were read immediately on a 
Titertek Multiskan PLUS MK II plate reader (Flow Labo- 
ratories, Mississauga, Ontario, Canada), using a test wave- 
length of 570 rim, and a reference wavelength of 650 rim. 
3. Results and discussion 
3.1. Synthesis of PDP-PEG-DSPE 
For preparation of S1Ls we chose the conjugation strat- 
egy shown in Fig. 1 for the following reasons. Reaction 
between thiol and maleimide groups is one of the most 
useful and efficient reactions in bioconjugate chemistry 
[6,36]. It takes place at close to neutral pH, at ambient 
temperature, within short periods of time, and often results 
in satisfactory ields of conjugates, even when relatively 
H2N+o+OH~ "n B°c20 m ,~O T H+ O~ U---]OH 
ot-amino-e)-hydroxy-PEG 
I 1. SPDP I DSC/Pyridine 
2. DCS / Pyridine 
O O 
" o H o O.O-N  
+ h oY 
PDP-PEG-SC Boc-PEG-SC 
~XX DSPE/TEA /
H r ] H 0 ® i01 
R-N ~ '~o '~O' ] l~N ~,~ O- ,~,- O H, , -~O"~'C  ~ ,H3, 
n O O O..N.~C17Has 
H 
4MHClindioxane C 1 R=Boc O 
R=H 
SPDP / TEA 
R = PDP 
D'FI" 
4 R='~ ~v/sH 
O 
Fig. 2. Synthetic pathways for PDP-PEG-DSPE. Both PDP-PEG-DSPE synthetic pathways tarted with the heterobifunctional polymer, oL-amino-~o-hy- 
droxy poly(ethylene glycol) [24]. On the right, o~-amino-~-hydroxy-PEG is coupled with SPDP then with DSPE. On the left, o~-amino-~o-hydroxy-PEG is 
first protected with Boc then bound to DSPE and subsequently Boc was removed and replaced with SPDP. Once incorporated into liposomes containing 
derivative 4, a free thiol was generated by reduction of PDP with DTT (see Materials and methods). 
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low concentrations of the reactants are present. Thus it 
seems to be particularly suitable for interlinking of two 
macromolecular entities. 
Previous experience with maleimide-PE incorporated 
into liposomes showed that it interfered with the drug 
loading procedures [8]. Maleimide is also known to un- 
dergo gradual degradation under conditions used during 
liposome preparation, sizing, and drug loading steps [6,37]. 
On the other hand, a maleimide group can be introduced 
onto IgG just prior to the actual conjugation step giving it 
no opportunity to undergo any side reactions. 
Thiol groups, while very reactive towards various elec- 
trophiles, can be preserved under non-oxidizing conditions. 
To absolutely assure the integrity of the thiol groups, we 
decided to prepare a protected form of thiol group (PDP) 
positioned at the terminus of PEG-DSPE. Thus, our strat- 
egy involved preparation of liposomes containing the new 
conjugate, PDP-PEG-DSPE, first. They were conveniently 
formulated and drug-loaded, and after reductive deprotec- 
tion of the reactive thiol groups with DTT, conjugated with 
maleimide-containing IgG (see Fig. 1). 
The two synthetic pathways leading to PDP-PEG-DSPE 
are schematically depicted in Fig. 2. The synthesis tarted 
with heterobifunctional polymer, c~-amino-~o-hydroxy 
poly(ethylene glycol), which was prepared by partial con- 
version of the hydroxyl end groups into primary amines 
[22] followed by ion-exchange purification of H 2 N-PEG- 
OH [23]. The amino group was selectively acylated with 
di-tert-butyldicarbonate r sulting in the introduction of 
Boc protecting roup. Proton-NMR obtained in DMSO-d 6 
confirmed the presence of the protecting roup as well as 
the unaltered hydroxyl. The remaining three steps of the 
synthesis were performed similarly to the previously pub- 
lished method for preparation of hydrazido-PEG-DSPE 
[39]. Briefly, a succinimidylcarbonate (SC) group, intro- 
duced at the hydroxy-end of the polymer, was used to form 
urethane attachment of the polymer to the amino group of 
DSPE yielding Boc-protected amino-PEG-DSPE (1) at the 
end of the PEG chain. The primary amine functionality 
was regenerated by acidolytic removal of the Boc-group 
forming 2. Finally, PDP-PEG-DSPE (3) was obtained by 
acylation of the terminal amino group with SPDP. 
Alternatively a-amino-oJ-hydroxy-PEG could be di- 
rectly reacted with SPDP substituting only the amino 
group. Then the remaining hydroxy end group was cleanly 
converted into succinimidyl carbonate and the resulting 
macromolecular analog of SPDP (PDP-PEG-SC) was cou- 
pled to DSPE. It appears that the second approach is 
preferable for a direct preparation of PDP-PEG-DSPE (3). 
It is two steps shorter and it resulted in higher yields of the 
product. The first approach is more general and allows 
conversion of amino-PEG-DSPE [24] into various func- 
tionalized PEG-DSPE-derivatized conjugates via use of 
different heterobifunctional reagents [38]. 
It is important o note that the utility of the new 
macromolecular crosslinker, PDP-PEG-SC clearly extends 
Table 1 
Coupling efficiency and Ab density in liposomes containing PDP-PEG- 
DSPE 
mol% mol% Initial Ab/PL  Ab density Coupling 
mPEG- PDP-PEG- molar ratio (/xg Ab /  efficiency 
DSPE DSPE /xmol PL) (%) 
3 2 1:250 316 51 
1 : 500 265 85 
1 : 1000 136 87 
4 1 1:1000 114 73 
1:2000 63 81 
4.5 0.5 1:500 82 26 
1:1000 76 48 
1:2000 66 85 
4.75 0.25 1:500 41 13 
1 : 1000 36 23 
1:2000 35 45 
5 0 1:500 11 3.4 
1:1000 10 6.1 
1:2000 7 9.5 
0 1 1 : 1000 93 60 
1:2000 69 88 
Liposomes were composed of HSPC/CHOL, 2:1 molar ratio and con- 
tained 5 mol% total PEG, consisting of a combination of mPEG-DSPE 
and PDP-PEG-DSPE as indicated. Liposomes averaged 100 nm in diame- 
ter. The source of Ab was sheep IgG and the Ab/PL  molar ratio in the 
coupling mixture (2 mM PL) was varied from 1:250 to 1:2000. The 
coupling procedure, schematically shown in Fig. 1, is described in detail 
in Materials and methods. The coupling efficiency is expressed as the % 
of initial Ab attached to the liposomes. 
beyond the current application. It is in a sense a PEG 
analog of SPDP and as such offers several advantages. 
Unlike SPDP, PDP-PEG-SC is water soluble. Since, PEG 
is a material of choice for rendering surfaces biocompati- 
ble, PDP-PEG-SC is perfectly suitable for linking ligands 
to biomaterials intended for blood plasma contact. It is 
ideally suited for preparation of two or more component 
macromolecular conjugates, e.g., protein-protein cross- 
linking. In this case, the PEG spacer, being very flexible 
and well solvated in water, would allow maximum free- 
dom of mobility for each of the conjugated components. 
3.2. Coupling of antibodies to liposomes containing PDP- 
PEG-DSPE 
The PDP-PEG-DSPE could be incorporated easily into 
liposomes during their formation and Ab could be effi- 
ciently coupled to the surface of liposomes containing 
PDP-PEG-DSPE following the reduction of the PDP group 
with DTT. A comparison of the effect of the PDP-PEG- 
DSPE content in the liposomes, and the effect of Ab/PL 
ratio on coupling efficiency and the Ab density conjugated 
at the liposome surface is given in Table 1. Higher mol% 
of PDP-PEG-DSPE incorporated into the liposomes re- 
suited in higher Ab densities at the liposome surface, with 
the highest densities being over 300 /xg Ab//xmol PL 
(Table 1) corresponding to approx. 150 Ab/100 nm diam- 
eter liposome, which is almost complete coverage of the 
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surface of the liposome. One can estimate that, at complete 
coverage, 200 Ab can be bound to a liposome 100 nm in 
diameter. These calculations were based on the following 
assumptions: the effective diameter of a IgG 1 molecule is 
142 A [40] (150000 Da), the area per polar head for HSPC 
is 72 ~2 and for CHOL is 19 ~2 [41] with an combined 
area per phospholipid of 81.5 ~2 for a HSPC/CHOL (2:1 
tool/tool) liposome. 
As the amount of PDP-PEG-DSPE in the liposomes 
was decreased, the Ab density at the liposome surface also 
decreased, but even at the lowest concentration of PDP- 
PEG-DSPE (0.25 tool%), substantial amounts of Ab still 
could be conjugated to the liposome surface (35-41 /xg 
Ab//xmol PL) (Table 1). In the absence of PDP-PEG- 
DSPE, very low amounts of Ab were associated with the 
liposomes (approx. 10/xg Ab//zmol PL), possibly through 
passive absorption (Table 1). 
When the initial Ab/PL  molar ratios were kept constant 
(e.g., 1:1000), the coupling efficiency decreased as the 
concentration of PDP-PEG-DSPE in the liposomes de- 
creased, from a high of 87% of the Ab attached to 
liposomes in the presence of 2 mo1% PDP-PEG-DSPE to a 
low of 23% in the presence of 0.25 mo1% PDP-PEG-DSPE 
(Table 1). Although Ab density decreased as the initial 
Ab /PL  molar ratio decreased, the coupling efficiency 
increased as this ratio decreased. A plot of coupling effi- 
ciency versus PDP-PEG-DSPE/Ab ratio demonstrates that 
the % of initial Ab bound to the liposomes reaches a 
maximum of greater than 80% above PDP-PEG-DSPE/Ab 
ratios of 10:1 (Fig. 3). In other words, for maximum 
coupling efficiency to occur, the PDP-PEG-DSPE must be 
present in approximately a 10-fold excess. 
In the absence of mPEG-DSPE in the liposomes, equiv- 
alent amounts of Ab became associated with the liposomes 
as in the presence of mPEG-DSPE, with similar coupling 
efficiencies (Table 1). This demonstrates that the Ab can 
gain easy access to its coupling site at the PEG terminus. 
100-  
80~ • 
o 
c 
• ~ 60 
40 
.S 
o .  
20-  
U 
0 I I F 
0 5 10 15 20 
PDP-PEG-DSPE:Ab  molar  ratio 
Fig. 3. Coupling efficiencies as a function of PDP-PEG-DSPE/Ab molar 
ratio. L iposomes  (100 nm in diameter),  composed of 
HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE (2:1:0.08:0.02 molar ra- 
tio), were coupled to Ab (sheep IgG) at various molar ratios of PDP- 
PEG-DSPE/Ab (2 mM phospholipid). The coupling efficiency is ex- 
pressed as the % of initial Ab bound to the liposomes. 
Table 2 
Coupling efficiency and Ab densities for liposomes containing PDP-DOPE 
Initial Ab/PL  Ab density Coupling 
molar ratio ( p~g Ab//xmol PL) efficiency (%) 
1:500 28 9 
1:1000 15 10 
1:2000 7.4 9 
Liposomes were composed of HSPC/CHOL, 2:1 molar ratio and con- 
tained 5 mol% mPEG-DSPE and 1 tool% PDP-DOPE. Liposomes aver- 
aged 100 nm in diameter. The source of Ab was sheep IgG and the 
Ab/PL  molar ratio in the coupling mixture (2 mM PL) was varied from 
1:500 to 1:2000. The coupling procedure was as outlined in Materials and 
methods. The coupling efficiency is expressed as the % of initial Ab 
attached to the liposomes. 
This is in contrast o methods where Ab is coupled at the 
liposome surface when mPEG can sterically interfere with 
access of Ab to its coupling site [8]. Further data in support 
of this conclusion is presented in Table 2. For liposomes 
containing PDP-DOPE and mPEG-DSPE (i.e., the PDP 
group is at the liposome surface), the coupling efficiency 
and Ab densities are significantly lower than for liposomes 
containing PDP-PEG-DSPE. We suggest that this is due to 
steric hinderance by mPEG-DSPE to access of maleimide- 
Ab to the reduced PDP groups (thiol-PE) at the liposome 
surface. 
3.3. Remote loading of doxorubicin and drug leakage rates 
In the PDP-PEG-PE coupling method, the MPB group 
is attached to the Ab rather than to the liposome surface, as 
in coupling methods using MPB-PE [6,7]. Hence the MPB 
group is present in much lower concentrations, and is 
located much further from the immunoliposome surface 
after conjugation, than in the MPB-PE method. DXR could 
be remote loaded into SL (HSPC/CHOL/mPEG-  
DSPE/PDP-PEG-DSPE, 2:1:0.08:0.02) prior to Ab conju- 
gation with greater than 95% efficiency after 1 h at 65 ° C. 
The half-life for release of doxorubicin from these lipo- 
somes, following conjugation of Ab was in excess of 150 
h. This is in contrast o the difficulties with the remote 
loading of doxorubicin into liposomes containing the MPB 
group at the liposome surface (MPB-PE method), where 
the presence of the hydrophobic MPB group at the lipo- 
some surface appears to significantly decrease the rate of 
loading of doxorubicin and increase the rate of drug 
leakage [8]. 
3.4. Pharmacokinetics of S-immunoliposomes formed by 
the PDP-PEG-DSPE method 
Immunoliposome clearance was determined with lipo- 
somes containing the aqueous pace label, ]25I-tyraminyl- 
inulin (]25I-TI). Free 125I-TI was removed from the body 
with a tj/2 of a few minutes, while the liposome-entrapped 
label had a long latency time in the body with a t~/2 of 78 
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h, indicating that the label had a very slow leakage rate 
from the liposomes in vivo. Leakage of the label was 
totally independent of the presence of Ab on the lipo- 
somes. The blood levels, as a function of time, for SIL 
containing increasing Ab densities (sheep IgG), formed by 
the PDP-PEG-PE method, are shown in Fig. 4A and B. 
Polyclonal sheep IgG was used for these experiments in
order to not to deplete our limited supplies of monoclonal 
antibodies, however in our experience, there is no differ- 
ence in the pharmacokinetics between polyclonal and mon- 
oclonal antibodies. 
The addition of PDP-PEG-DSPE into S-liposomes (no 
Ab) did not significantly alter their circulation t imes  (tt/2 
of 16 h, with greater than 80% of the label remaining 
liposome entrapped and therefore remaining in vivo). The 
SIL were removed from circulation in a log-linear manner 
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Fig. 4. Blood clearance kinetics of S-immunoliposomes in mice. Anti- 
body (sheep IgG) was coupled at various densities to liposomes 
(HSPC/CHOL/PDP-PEG-DSPE, 2:1:0.02 molar ratio +4 tool% 
mPEG-DSPE, 100 nm diameter) containing the aqueous space label 
125I-TI. The resulting S-immunoliposomes were injected i.v., via the tail 
vein, into CD I (ICR) mice. Results are expressed as label remaining in 
blood as a percentage of the label remaining in the body at various times 
post injection (means + S.D., n = 3). (A) Blood clearance of S-immuno- 
liposomes as a function of time and Ab density. Liposomes contained 
various Ab densities in the presence of mPEG-DSPE (0 )  no Ab; ( • ) 20 
/xg Ab//xmol PL; (• )  40 p~g Ab//~mol PL; (• )  74/.zg Ab/p ,  mol PL; 
( • ) 140 /xg Ab /~mol  PL. Control liposomes ( • ) contained no mPEG- 
DSPE, and had an antibody density of 73 /zg Ab//~mol PL. (B) Blood 
clearance of SIL at 24 h post-injection as a function of Ab density. 
at Ab densities of 74 /zg//xmol PL and lower (Fig. 4A) 
and the level of SIL in blood at 24 h decreased with an 
increase in the Ab density (Fig. 4B). High Ab densities 
(140 /~g//~mol PL) resulted in rapid removal of the SIL 
from circulation (Fig. 4A and B), but no change in the rate 
of label leakage from the liposomes. Ab densities in the 
range of approx. 20-80 /zAb//xmol PL resulted in tj/2 in 
the circulation of from 7 to 9 h compared to 16 h in the 
absence of Ab (with greater than 90% of the entrapped 
liposome label remaining in vivo), which is likely to be 
sufficiently long to allow in vivo targeting. By contrast, 
liposomes lacking mPEG (73 tzg Ab//xmol PL) were 
rapidly removed from circulation (Fig. 4A) even at low Ab 
densities, with half-lives of less than 0.5 h. 
3.5. Binding to, and cytotoxici~, to, cancer cells in culture 
by S-immunoliposomes 
The binding by three different cancer cell lines, of SIL 
conjugated by the PDP-PEG-PE method to three different 
mAb specific for each cell line, is shown in Fig. 5. In each 
case the attachment of a specific mAb to SIL 
(SIL[ 174H.64], SIL[B43.13] or SIL[M 170]) resulted in 2-to 
3-fold increased binding of the SIL to their respective cell 
lines (KLN-205, Fig. 5A; Caov.3, Fig. 5B; or HCT-15, 
Fig. 5C). Increasing the Ab density at the liposome surface 
resulted in a modest increase in the amount of SIL bound 
to the KLN-205 cells (Fig. 5A). We have previously 
shown that an isotype matched non-specific Ab (B27.29, 
Biomira) conjugated to immunoliposomes by the PDP- 
PEG-PE method showed no increase in binding to KLN- 
205 cells compared with antibody-free liposomes [42,43]. 
Excess free mAb 174H.64 would compete for binding of 
SIL[174H.64] to KLN-205 cells, but free mAb B27.29 was 
not effective in displacing binding of SIL[174H.64] [42]. 
Incubation of HCT-15 cells in the presence of 10% FBS 
reduced the binding of SL (no mAb) and SIL[MI70] to the 
cells by approx. 2-fold, but the increase in binding of SIL 
compared with SL was, if anything, greater in the presence 
of serum than in its absence (Fig. 5D versus 5C). 
The ability of SIL[174H.64] to increase the cytotoxicity 
of entrapped DXR to KLN-205 cells was also examined 
(Table 3). The ICs0 for DXR-SIL[174H.64] at 1 h incuba- 
tion was lower than that for either free DXR or DXR-SL. 
For this short incubation time, the free DXR and DXR-SL, 
both of which would be expected to have only low levels 
of non-specific association with the cells, were likely 
washed away before the drug could be taken up into cells 
in significant amounts. In addition, the very high IC~0 for 
DXR-SL is likely also due to the sequestration f the DXR 
inside liposomes, with relatively little DXR released from 
the liposomes during the 1 h incubation period. As antici- 
pated, free DXR and DXR-SL had significantly lower ICso 
after a 24 h incubation, while the SIL[174H.64] appeared 
to have reached close to its maximum cytotoxicity after I 
h incubation and only experienced a slight decrease in ICs0 
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Table 3 
Cytotoxicity of SIL[174H.64] against murine squamous lung carcinoma 
cells in culture 
Sample ICs0, /~g DXR/ml of media for KLN 205 cells 
I h incubation 24 h incubation 
Free DXR 93 15 
DXR-SL > 200 68 
DXR- 42 3 I 
SIL[174H.64] 
Murine squamous lung carcinoma (KLN 205) cells were plated in 96-well 
plates on day 1. 24 h later, free DXR, DXR-SL or DXR-SIL[174H.64] 
was incubated with the cells for 1 h or 24 h prior to gently washing the 
cells three times with phosphate-buffered saline, pH 7.4. The cells were 
then incubated for a further 47 or 24 h, respectively (total incubation 
time, 48 h). The IC5~  ( ~g DXR/ml) was determined from cell viability 
using a tetrazolium dye assay [35]. 
after 24 h. At 24 h, SIL[174H.64] were slightly less 
cytotoxic than free DXR, although more cytotoxic than 
DXR-SL. It would appear that the I h incubation period 
was sufficient for binding and/or internalization of the 
SIL[174H.64] to liposomes, as the longer incubation time 
did not result in very large increases in cytotoxicity for 
these liposomes. The 1 h incubation would be more similar 
to the in vivo situation, where free DXR would be rapidly 
distributed throughout he body in a large volume of 
distribution [44,45], with tumor cells exposed to relatively 
low concentrations of the drug. The SIL, on the other 
hand, when bound to tumor cells in vivo, might be ex- 
pected to deliver higher amounts of drug to the tumor in a 
sustained manner, either through release of locally high 
concentrations of drug from SIL bound at the tumor 
surface and uptake of DXR through the normal uptake 
mechanisms, or through Ab-mediated intenlalization of the 
drug-liposome package. At present we are undertaking 
experiments to distinguish between the relative contribu- 
tion of these two mechanisms of SIL-mediated cytotoxic- 
ity, however, independent of the mechanism of cytotoxic- 
ity, we have recently demonstrated a dramatic increase in 
mean survival time of mice inoculated with the KLN-205 
cell line and treated with DXR-SIL[174H.64] relative to 
DXR-SL or free DXR [46]. 
In conclusion, we developed a simple 3 step synthesis 
of new end-group functionalized PEG-lipid, PDP-PEG- 
DSPE, starting from a-amino-w-hydroxy-PEG. Incorpora- 
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Fig. 5. Binding of S-immunoliposomes by various tumor cell lines. S-immunoliposomes in PBS (HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE. 
2:1:0.08:0.02 molar ratio, 100 nm in diameter) were labelled with 3H_CHE and incubated for I h at 37 ° C with cells at a liposome concentration f 0.1-0.4 
/xmol PL/ml. (A) Murine squamous lung carcinoma (KLN205) and mAb 174H.64 coupled to SIL; (B) Human ovarian adenocarcinoma (Caov-3) and 
mAb B43.13 coupled to SIL; (C) human colon adenocarcinoma (HCT-15) and mAb M170 coupled to S1L. (D) HCT-15 cells and mAb MI70 coupled to 
SIL incubated in the presence of 10% FBS. means ± S.D,, n = 3. 
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tion of this PEG-lipid conjugate into liposomes allows for 
convenient generation of thiol groups at the distal ends of 
the grafted PEG chains. Incubation of the vesicles contain- 
ing thiol-PEG-DSPE (4) with maleimide-antibodies re- 
sulted in efficient conjugation even when content of the 
functionalized PEG-DSPE component in the liposomes 
was below 1 mol%. This method realizes many of the 
criteria which would be desirable for 'ideal' S-immuno- 
liposomes including simplicity, high coupling efficiency, 
the ability to achieve a large range of Ab densities at the 
liposome surface, significantly increased survival times in 
circulation compared to classical immunoliposomes, effi- 
cient drug loading, slow drug release rates, and retention 
of target binding. 
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